loratadine and labetalol

loratadine has been researched along with labetalol in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carrupt, PA; Jolliet, P; Morin, C; Morin, D; Pagliara, A; Rihoux, JP; Testa, B; Tillement, JP; Urien, S1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Glen, RC; Lowe, R; Mitchell, JB1
Gunaydin, H; Sun, Y; Weiss, MM1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for loratadine and labetalol

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for loratadine and labetalol

ArticleYear
Molecular properties and pharmacokinetic behavior of cetirizine, a zwitterionic H1-receptor antagonist.
    Journal of medicinal chemistry, 1998, Mar-12, Volume: 41, Issue:6

    Topics: Alkanes; Animals; Biological Transport; Blood Proteins; Brain; Cetirizine; Histamine H1 Antagonists; Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydroxyzine; Isomerism; Models, Molecular; Molecular Conformation; Octanols; Rats; Water

1998
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Predicting phospholipidosis using machine learning.
    Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5

    Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine

2010
De novo prediction of p-glycoprotein-mediated efflux liability for druglike compounds.
    ACS medicinal chemistry letters, 2013, Jan-10, Volume: 4, Issue:1

    Topics:

2013